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Abstract. Recently it has been hypothesized that vanadium 
serves a carcinogenic role in the thyroid. However, to date, no 
in vivo or in vitro studies have evaluated thyroid disruption 
in humans and/or animals following exposure to vanadium. 
The present study evaluated the effect of vanadium pentoxide 
(V2O5) on cell viability and proliferation, and chemokine 
(C-X-C motif) ligand (CXCL)8 and CXCL11 secretion in 
normal thyrocytes. The results demonstrated that V2O5 had 
no effect on thyroid follicular cell viability and proliferation. 
However, V2O5 was able to induce the secretion of CXCL8 and 
CXCL11 chemokines from thyrocytes. Notably, V2O5 syner-
gistically increased the effect of the interferon (IFN)-γ on 
CXCL11 secretion. In addition, V2O5 synergistically increased 
the effect of tumor necrosis factor-α on CXCL8 secretion, and 
abolished the inhibitory effect of IFN-γ. Overall this induction 
of CXCL8 and CXCL11 secretion may lead to the induction 
and perpetuation of an inflammatory reaction in the thyroid. 
Further studies are now required to evaluate thyroid function 
and nodule development in subjects who are occupationally 
exposed, or living in polluted areas.
Introduction
Vanadium pentoxide (V2O5) is the most common form of 
vanadium, a grey metal existing in different states of oxidation 
(-1, 0, +2, +3, +4, and +5). The majority of vanadium compounds 
are considered to be toxic.
The Occupational Safety and Health Administration 
(OSHA) fixed a workplace threshold for V2O5 in the air 
of 0.05 mg/m3 for the dust and 0.1 mg/m3 for fumes (when 
considering an 8 h workday/40 h work week) (1). Exposure 
to a 35 mg/m3 dose of vanadium it is considered dangerous 
and may provoke serious and perpetual health issues that can 
lead up to death [as established by The National Institute for 
Occupational Safety and Health (NIOSH)] (1). The toxic effects 
of vanadium mainly impact the respiratory system; effects on 
the gastrointestinal system are less relevant due to the minimal 
gut absorption rate of the substance (2-4). However, due to 
insufficient data, it is not possible to determine the reference 
range of a subchronic or chronic inhaled dose at present.
Previous studies have evaluated the effects of oral or 
inhaled vanadium exposures on serum parameters (5,6), on 
liver (7), and nervous system (8), and other tissues (9), in rat 
models.
It has been recently suggested that volcanic pollution exerts 
a carcinogenic effect. Indeed, the incidence of thyroid cancer 
registered in the Mount Etna volcanic area was found to be 
higher with respect to a control area (18.5 and 9.6/105 inhab-
itants, respectively). Many trace elements are increased in 
volcanic areas compared with control areas, in both drinking 
water and lichens, indicating both water and atmospheric 
pollution; among all the increased elements, vanadium was 
8 times higher, suggesting that it is a major determinant in the 
carcinogenic effect of volcanic pollution on the thyroid (10,11). 
To date, however, no in vivo or in vitro studies have evalu-
ated thyroid/endocrine disruption in humans and/or animals 
following vanadium exposure.
Recently, it has been investigated whether the secretion 
of chemokine (C-X-C motif) ligand (CXCL)8 and CXCL10 
by normal human thyrocytes is dependent upon specific 
proinflammatory stimuli. The secretion of CXCL8 but not of 
CXCL10 has been detected under basal conditions from thyro-
cytes. Furthermore, the two chemokines show differences 
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in their response to proinflammatory cytokines. Indeed, 
significant secretion of CXCL10 was induced by interferon 
(IFN)-gamma and not by tumor necrosis factor (TNF)-alpha, 
whereas CXCL8 was secreted in response to TNF-alpha, 
while being inhibited by IFN-gamma; meanwhile, a combina-
tion of TNF-alpha plus IFN-gamma synergistically increased 
the IFN-gamma-induced CXCL10 secretion, while reducing 
the TNF-alpha-induced CXCL8 secretion (12).
Moreover, it has been recently shown that CXCL10 mRNA 
and protein levels were increased by V2O5 (13), and V2O5 expo-
sure is a cause of occupational bronchitis, as a study evaluated 
gene expression profiles in human lung fibroblasts (in cultures) 
after V2O5 exposure, showing that among the 10 genes over-
expressed by V2O5, also CXCL8, CXCL9 and CXCL10 were 
induced (14).
For these reasons, we evaluate the effect of V2O5 on the 
secretion of CXCL8 and CXCL11 chemokines from normal 
thyrocytes.
Materials and methods
Thyroid follicular cells. We obtained samples of thyroid tissue 
from 10 euthyroid patients (5 females and 5 males, mean age, 
41 years; age range, 24-61), of whom 8 had undergone prior 
parathyroidectomy, and 2 had undergone laryngeal interven-
tion. Written informed consent for the study was obtained 
from all patients, and the study was approved by the local 
Ethical Committee of the University of Pisa (Pisa, Italy).
Thyrocytes were prepared from the tissue samples, as 
reported previously (15-17). In brief, the tissue samples were 
digested with collagenase (Roche, Mannheim, Germany; 
1 mg/ml) with RPMI 1640 medium (Whittaker Bioproducts, 
Inc., Walkersville, MD, USA) for 1 h at temperature of 37˚C. 
Subsequently, semi-digested follicles were removed and 
sedimented for 2 min; they were then washed and cultured 
with RPMI 1640 containing 10% fetal bovine serum (FBS) 
(Seromed, Berlin, Germany), 50 mg/ml penicillin/strepto-
mycin and 2 mM glutamine with 5% CO2 at 37˚C. The cells 
were all used at the 4th passage.
Cell viability and proliferation assay. We assessed cell viability 
and proliferation with a WST-1 assay (Roche Diagnostics, 
Almere, The Netherlands), which is based on the use of 
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide 
of the MTT assay (17-19). We seeded thyroid follicular cells 
(TFC) in each well of a 96-well plate at a concentration of 
35,000 cells/ml in a final volume of 100 µl. To evaluate the 
effects of V2O5 on TFC viability and proliferation, we treated 
the TFC for 24 h with increasing concentrations of V2O5 
(1, 10 and 100 nM). The experiments were performed in tripli-
cate for each cell preparation. The plated cells were treated for 
24 h with V2O5 or its vehicle alone.
Proliferation assay: Cell counting. As the cell viability 
and proliferation WST-1 assay may have limitations on 
evaluating cellular proliferation (20), we also performed cell 
number counting to evaluate the proliferation of the TFCs 
[see above (18,19,21-23)]. In the cell counting method, cells 
were seeded at a density of 13,000 cells per well in 24-well 
tissue culture plates in a medium supplemented with 10% 
v/v FBS, with increasing concentrations of V2O5 (1, 10 
and 100 nM). After 24 h in an atmosphere of 5% CO2 and 
95% air at 37˚C, the cells were detached from the plates by 
incubation with 500 ml phosphate-buffered saline (PBS) 
containing 100 mg trypsin and 1 mmol/l ethylenediamine-
tetraacetic acid (EDTA). The cells were then counted using a 
haemocytometer (18,19,21-23).
Chemokine secretion assay and ELISA. To analyse CXCL8, 
CXCL11 and nuclear factor-κB (NF-κB) secretion, cells were 
seeded in 96-well plates at a concentration of 30,000 cells/ml 
in a final volume of 100 µl/well in growth medium, which 
was removed after 24 h. The seeded cells were washed in 
PBS, then incubated, for 24 h in phenol red and serum-free 
medium with IFN-gamma (R&D Systems, Minneapolis, 
MN, USA; 500; 1,000; 5,000 and 10,000 IU/ml), and 
10 ng/ml TNF-alpha (R&D Systems), alone or in combina-
tion (16). We performed preliminary experiments to select 
the TNF-alpha concentration, in order to achieve maximal 
responses (data not shown).
To evaluate how V2O5 may affect chemokine secretion 
induced by IFN-gamma, we exposed the cells for 24 h to 
increasing concentrations of V2O5 (1, 10 and 100 nM) in the 
presence or absence of IFN-gamma (1,000 IU/ml), and/or 
TNF-alpha (10 ng/ml).
An ELISA assay was used to evaluate CXCL8, CXCL11 
and nuclear factor-κB (NF-κB) concentrations in the superna-
tants. The experiments were carried out three times with each 
different cell preparation.
CXCL11 and CXCL8 levels were measured in the culture 
supernatants with commercially available kits (R&D Systems). 
The mean minimum detectable dose was 2.9 pg/ml for CXCL8 
and 3.4 pg/ml for CXCL11; the intra‑ and inter‑assay coeffi-
cients of variation were 3.4 and 6.2% for CXCL8, and 4.9 and 
8.3% for CXCL11. NF-κB levels were measured in the culture 
supernatants by ELISA (Antibodies online; product no. ABIN 
414848). The mean minimum detectable dose was 0.15 ng/ml 
(detection range, 0.15-10 ng/ml).
Quality control pools of low, normal, and high concentra-
tion for all parameters were included in each assay.
Statistical analysis. Values are presented as the mean ± standard 
deviation for normally distributed variables (in text), or as the 
mean ± standard error mean (in figures), or as the medians 
and interquartile range. Mean group values were compared 
using one-way analysis of variance for normally distributed 
variables, or the Mann-Whitney U or Kruskal-Wallis test was 
performed. Proportions were compared with the Chi-Square 
test. For multiple comparisons, the post-hoc Bonferroni-Dunn 
test was applied for comparisons on normally distributed 
variables.
Results
Cell viability and proliferation. Cell counting showed that 
V2O5 (1, 10 or 100 nM) did not change the viability or prolifera-
tion rate of TFCs (Fig. 1). These results were confirmed by the 
WST-1 assay (data not shown). Meanwhile, when treating TFC 
cells with V2O5 at 250 and 500 nM, viability and proliferation 
was inhibited by 17 and 28%, respectively (Fig. 1).
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CXCL8 secretion from TFC cells. CXCL8 secretion was 
measured for all cultured thyroid cell preparations, and 
under basal conditions, ranged from 37.8 to 173.5 pg/ml 
(Fig. 2A). This secretion increased dose-dependently with 
increasing concentrations of TNF-alpha (1, 5 and 10 ng/ml), 
with the highest response obtained with 10 ng/ml TNF-alpha 
(basal 94±32 pg/ml vs. TNF-alpha 931±257 pg/ml; P<0.01) 
(Fig. 2A).
By contrast, IFN‑gamma (1,000 IU/ml) significantly inhib-
ited the basal CXCL8 secretion (IFN-gamma 28±16 pg/ml vs. 
basal; P<0.05) (Fig. 2B). Furthermore, the stimulatory effect 
of TNF‑alpha was significantly reversed after the addition 
of IFN-gamma (TNF-alpha+IFN-gamma 412±141 pg/ml 
vs. TNF-alpha 931±257 pg/ml; P<0.05) (Fig. 2B). However, 
IFN-gamma did not completely reverse the stimulatory effect 
of TNF-alpha on the secretion of CXCL8, as CXCL8 concen-
tration remained significantly higher with respect to the basal 
conditions (TNF-alpha+IFN-gamma vs. basal; P<0.01).
CXCL8 release was also dose-dependently stimulated from 
thyrocytes following treatment with V2O5 (1, 10 and 100 nM) 
(ANOVA, P<0.0001) (Fig. 3A). When treating thyrocytes with 
V2O5 (100 nM) together with IFN-gamma, CXCL8 release was 
not significantly changed with respect to the basal level, and 
the inhibitory effect of IFN-gamma was not observed; however 
the stimulatory effect of V2O5 was abolished (Fig. 3B).
CXCL8 release was synergistically increased (ANOVA, 
P<0.0001) when cells were treated with V2O5 (100 nM) 
together with TNF-alpha, compared to TNF-alpha alone 
(Fig. 3C). Additionally, when treating thyrocytes with V2O5 
(100 nM), plus IFN-gamma and TNF-alpha, CXCL8 release 
was synergistically increased (ANOVA, P<0.0001), and the 
inhibitory effect of IFN-gamma was abolished (Fig. 3D).
CXCL11 secretion from TFC cells. CXCL11 was not detectable 
in the supernatants obtained from primary thyrocyte cultures. 
IFN-gamma dose-dependently induced CXCL11 release 
(CXCL11 level: 0, 26±13, 65±25, 102±32, 145±48 pg/ml; 
respectively, with IFN-gamma at 0; 500; 1,000; 5,000 and 
10,000 IU/ml; ANOVA, P<0.001), whereas TNF-alpha alone 
had no effect (CXCL11 remained undetectable). The combina-
tion of IFN‑gamma and TNF‑alpha had a significant synergistic 
effect on CXCL11 secretion (CXCL11 level, 1,354±132 vs. 
65±25 pg/ml with IFN-gamma alone, ANOVA, P<0.0001).
CXCL11 release was dose-dependently stimulated from 
thyrocytes following treatment with V2O5 (1, 10 and 100 nM) 
(ANOVA, P<0.0001) (Fig. 4A). This CXCL11 release was 
not significantly changed on treatment of the cells with V2O5 
(100 nM) together with TNF-alpha compared with V2O5 
treatment alone (data not shown). Meanwhile, V2O5 (100 nM) 
together with IFN-gamma synergistically increased CXCL11 
release (ANOVA, P<0.0001) (Fig. 4B). CXCL11 release was 
also synergistically increased (ANOVA, P<0.0001) when 
thyrocytes were treated with V2O5 (100 nM) together with 
IFN-gamma and TNF-alpha (Fig. 4C).
NF‑κB secretion from TFC cells. NF-κB levels were measured 
in the supernatants obtained from primary thyrocyte cultures. 
NF-κB release was dose-dependently stimulated by treating 
thyrocytes with V2O5 (1, 10 and 100 nM), with respect to 
control treatment (ANOVA, P<0.005). NF-κB was increased 
by 4% vs. the control with 1 nM V2O5; by 16% vs. the control 
with 10 nM V2O5; and by 31% vs. the control with 100 nM 
V2O5 (Fig. 5).
Figure 2. CXCL8 secretion from thyroid follicular cells following TNF-α 
and/or IFN-γ treatment. (A) CXCL8 secretion was measured in all cultured 
thyroid cell preparations in basal conditions (Control). CXCL8 secretion 
increased dose-dependently with increasing concentrations of TNF-α (1, 5 
and 10 ng/ml), with the highest response obtained with 10 ng/ml TNF-α. 
(B) IFN-γ (1,000 IU/ml) significantly inhibited basal CXCL8 secretion. The 
stimulatory effect of TNF-α was significantly reversed following the addition 
of IFN-γ. IFN-γ did not completely reverse the stimulatory effect of TNF-α 
on the secretion of CXCL8, as the CXCL8 concentration remained signifi-
cantly higher with respect to basal conditions. *P<0.05 vs. control; #P<0.05 
vs. IFN+TNF; $P<0.05 vs. TNF; ∆P<0.05 vs. IFN. CXCL8, chemokine (C-X-C 
motif) ligand 8; TNF, tumor necrosis factor; IFN, interferon.
Figure 1. Cell viability and proliferation. Cell counting analysis revealed that 
V2O5 (1, 10 and 100 nM) did not change the viability and proliferation rate 
of thyroid follicular cells, while 250 and 500 nM reduced it by 17 and 28%, 
respectively. *P≤0.05 vs. control. V2O5, vanadium pentoxide.
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Discussion
Our results show that V2O5 can promote the secretion of CXCL8 
and IFN-gamma dependent CXCL11 secretion from TFCs, 
without altering the viability and proliferation of the cells. 
Moreover, our study confirmed that IFN‑gamma and TNF‑alpha 
stimulated CXCL11 secretion as expected (17). Interestingly, 
CXCL11 secretion was increased by V2O5 combined with 
IFN‑gamma and TNF‑alpha. Furthermore, a synergistic influ-
ence on CXCL8 secretion was elicited by V2O5 combined 
with TNF-alpha, which abolished the inhibitory effect of 
IFN-gamma. Our results, on the whole, suggest that V2O5 can 
induce and perpetuate an inflammatory disorder in the thyroid 
by inducing the secretion of inflammatory chemokines (18).
CXCL8, also called neutrophil chemotactic factor, has two 
primary functions: it induces chemotaxis in target cells, espe-
cially neutrophils but also other granulocytes, causing them 
to migrate toward the site of infection; it is a potent promoter 
of angiogenesis and it is often associated with inflammation.
Whether the secretion of CXCL8 and CXCL10 by normal 
human thyrocytes depends on specific proinflammatory stimuli 
has been recently investigated. CXCL8 but not CXCL10 was 
detected in basal conditions. The two chemokines showed 
differences in their response to proinflammatory cytokines, as 
a significant secretion of CXCL10 was induced by IFN‑gamma 
and not TNF-alpha, while CXCL8 was secreted in response 
to TNF-alpha and inhibited by IFN-gamma. The combination 
of TNF-alpha and IFN-gamma synergistically increased the 
IFN-gamma-induced CXCL10 secretion, and reversed the 
TNF-alpha-induced CXCL8 secretion (12).
It has recently been suggested that CXCL8 sustains a 
first step toward a differentiation between autoimmune and 
tumor‑related inflammation in the thyroid (12). Therefore, it is 
feasible that the induction of CXCL8 secretion from thyrocytes 
by V2O5 could sustain a tumor‑related inflammatory response 
in the thyroid.
CXCL11 binds to the same chemokine receptor CXCR3 
as CXCL10 but with higher affinity and potency; its expres-
sion is strongly increased in response to IFN-gamma and is 
involved in the recruitment of T-helper 1 (Th1)  lymphocytes 
to sites of inflammation.
Furthermore, several types of normal mammalian 
cells (such as thyrocytes, fibroblasts, colon epithelial 
cells, islet cells and others) (15-19,21,24,25) can produce 
IFN-gamma-inducible C-X-C chemokines. However, these 
cells are not able to produce the C-X-C chemokines under 
basal conditions, but only after stimulation by cytokines such 
as IFN-gamma and TNF-alpha, which are generally secreted 
in a Th1 type inflammatory sites, such as the thyroid at the 
beginning of Graves' disease, by Th1-activated lymphocytes. 
This process has been suggested to be involved in the initiation 
and the perpetuation of the inflammation in several autoim-
mune diseases (15-19,21,24-27), and on the basis of our results 
may be applicable to the thyroid.
Moreover, our results showed a dose-dependent increase 
in NF-κB release following the treatment of thyrocytes with 
V2O5 with respect to control treatment. NF-κB is a transcrip-
tion factor found in almost all animal cell types, that is 
involved in cellular responses to stimuli (such as bacterial or 
viral antigens, stress, cytokines, heavy metals, free radicals, 
ultraviolet irradiation, and others) and has a determinant role 
in regulating the immune response. Its increase in our study 
suggests that vanadium may act on the NF-κB pathway to 
induce a final effect on chemokines, which is in agreement 
Figure 3. CXCL8 secretion from thyroid follicular cells following V2O5 and/or TNF-α and/or IFN-γ treatment. (A) CXCL8 release was dose-dependently 
stimulated by the treatment of thyrocytes with V2O5 (1, 10 and 100 nM). (B) Following treatment with V2O5 (100 nM) together with IFN-γ, CXCL8 release 
was not significantly altered with respect to basal conditions, and the inhibitory effect of IFN‑γ was not observed; however the V2O5 stimulatory effect was 
abolished. (C) CXCL8 release was synergistically increased when cells were treated with V2O5 (100 nM) together with TNF-α. (D) Following treatment 
with V2O5 (100 nM) plus IFN-γ and TNF-α stimulation, CXCL8 release was synergistically increased, abolishing the inhibitory effect of IFN-γ. *P<0.05 vs. 
control; $P<0.05 vs. IFN+V2O5; #P<0.05 vs. IFN+TNF+V2O5; ∆P<0.05 vs. TNF. CXCL8, chemokine (C-X-C motif) ligand 8; TNF, tumor necrosis factor; V2O5, 
vanadium pentoxide; IFN, interferon.
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with other studies reporting an association between CXCL8 or 
CXCL11 secretion and the NF-κB pathway (28-31).
The results of our study agree with those of other research 
on different cell types. V2O5 exposure is a cause of occupational 
bronchitis, and a previous study evaluated gene expression 
profiles in human lung fibroblasts (in cultures) after in vitro 
exposure to V2O5 , aiming to identify genes that could have 
a role in bronchial inflammation, repair, and fibrosis in the 
pathogenesis of bronchitis. About twelve genes were overex-
pressed in response to V2O5 among which were CXCL8 and the 
IFN-gamma-dependent chemokines CXCL9 and CXCL10 (14).
Interestingly, vanadium was able to increase chemokine 
secretion over a dose range from 1 to 100 nM. It has been 
reported that normal blood levels of vanadium range from 0.45 
to 18.4 nM, and that 100 nM is a dose that may mimic an 
abnormally high exposure (32).
Many studies conducted on mice have investigated the 
mechanism through which V2O5 induces lung cancer. In vivo 
and in vitro research suggests that lung cancers are induced 
by secondary mechanisms, rather than direct genotoxic 
pathways (33). Therefore, it may also be hypothesized that 
the induction of an inflammatory reaction in the thyroid may 
predispose for the development of thyroid cancer, as recently 
seen for autoimmune thyroiditis.
In conclusion, our study shows that V2O5 is able to induce 
the secretion of the chemokines CXCL8 and CXCL11 in the 
thyroid. Interestingly, V2O5 synergistically increased the effect 
of IFN-gamma on CXCL11 secretion. Moreover, V2O5 synergis-
tically increased the effect of TNF-alpha on CXCL8 secretion, 
abolishing the inhibitory effect of IFN-gamma. On the whole, 
these findings indicate that induction of CXCL8 and CXCL11 
secretion may lead to the induction and perpetuation of an 
inflammatory reaction in the thyroid. Further studies are now 
necessary to investigate the mechanism of action at the basis 
of this induction, and to evaluate thyroid function and nodule 
development in occupationally and environmentally exposed 




No funding was received.
Availability of data and materials
All data generated or analyzed during this study are included 
in this published article.
Authors' contributions
PF, RF, AC, AA and SMF made substantial contributions to 
the conception and design of the study, and to the acquisition 
of data. GE, FR, AP, GF and SB analysed the data. PF, AA and 
SMF drafted the manuscript, and AA revised it critically for 
important intellectual content. All authors read and approved 
the final manuscript.
Ethics approval and consent to participate
Written informed consent for the present study was obtained 
from all patients, and the study was approved by the local 
Ethical Committee of the University of Pisa (Pisa, Italy).
Figure 5. NF-κB release from thyroid follicular cells following V2O5 treat-
ment. NF-κB release was dose-dependently stimulated by treating thyrocytes 
with V2O5 (1, 10 and 100 nM), with respect to control treatment. *P<0.05 vs. 
Control. V2O5, vanadium pentoxide; NF, nuclear factor.
Figure 4. CXCL11 secretion from thyroid follicular cells. (A) CXCL11 release 
was dose-dependently stimulated from thyrocytes treated with V2O5 (1, 10 and 
100 nM). (B) Following treatment with V2O5 (100 nM) together with IFN-γ, 
CXCL11 release was synergistically increased. (C) CXCL11 release was syner-
gistically increased from thyrocytes treated with V2O5 (100 nM) together with 
IFN-γ and TNF-α. *P<0.05 vs. control; ∆P<0.05 vs. IFN; $P<0.05 vs. V2O5; 
#P<0.05 vs. IFN+TNF. CXCL11, chemokine (C-X-C motif) ligand 11; TNF, 
tumor necrosis factor; V2O5, vanadium pentoxide; IFN, interferon.
FALLAHI et al:  VANADIUM INDUCES CXCL8 AND CXCL11 CHEMOKINES IN THYROCYTES7420
Consent for publication
Written informed consent was obtained from all participating 
patients.
Competing interests
The authors declare that they have no competing interests.
References
 1. Occupational safety and health administration: Occupational 
safety and health guidelines for vanadium pentoxide. https://
www.osha.gov/SLTC/healthguidelines/vanadiumpentoxidedust/
recognition.html. Accessed January 29, 2009.
 2. Sax NI: Dangerous properties of industrial materials. 6th edtion. 
Van Nostrand Reinhold Company, New York, pp2717-2720, 1984.
 3. Ress NB, Chou BJ, Renne RA, Dill JA, Miller RA, Roycroft JH, 
Hailey JR, Haseman JK and Bucher JR: Carcinogenicity of 
inhaled vanadium pentoxide in F344/N rats and B6C3F1 mice. 
Toxicol Sci 74: 287-296, 2003. 
 4. Wörle-Knirsch JM, Kern K, Schleh C, Adelhelm C, Feldmann C 
and Krug HF: Nanoparticulate vanadium oxide potentiated 
vanadium toxicity in human lung cells. Environ Sci Technol 41: 
331-336, 2007. 
 5. Scibior A, Zaporowska H and Ostrowski J: Selected haema-
tological and biochemical parameters of blood in rats after 
subchronic administration of vanadium and/or magnesium in 
drinking water. Arch Environ Contam Toxicol 51: 287-295, 2006. 
 6. González-Vil la lva A, For toul TI, Avi la-Costa MR, 
Piñón-Zarate G, Rodriguez-Laraa V, Martínez-Levy G, 
Rojas-Lemus M, Biza r ro-Nevarez P,  Díaz-Bech P, 
Mussali-Galante P and Colin-Barenque L: Thrombocytosis 
induced in mice after subacute and subchronic V2O5 inhalation. 
Toxicol Ind Health 22: 113-116, 2006. 
 7. Kobayashi K, Himeno S, Satoh M, Kuroda J, Shibata N, Seko Y 
and Hasegawa T: Pentavalent vanadium induces hepatic metallo-
thionein through interleukin-6-dependent and -independent 
mechanisms. Toxicology 228: 162-170, 2006. 
 8. Soazo M and Garcia GB: Vanadium exposure through lacta-
tion produces behavioral alterations and CNS myelin deficit in 
neonatal rats. Neurotoxicol Teratol 29: 503-510, 2007. 
 9. Barceloux DG: Vanadium. J Toxicol Clin Toxicol 37: 265-278, 
1999. 
10. Malandrino P, Russo M, Ronchi A, Minoia C, Cataldo D, 
Regalbuto C, Giordano C, Attard M, Squatrito S, Trimarchi F 
and Vigneri R: Increased thyroid cancer incidence in a basaltic 
volcanic area is associated with non-anthropogenic pollution and 
biocontamination. Endocrine 53: 471-479, 2016. 
11. Ferrari SM, Fallahi P, Antonelli A and Benvenga S: Environmental 
issues in thyroid diseases. Front Endocrinol (Lausanne) 8: 50, 
2017. 
12. Rotondi M, Coperchini F, Pignatti P, Sideri R, Groppelli G, 
Leporati P, La Manna L, Magri F, Mariotti S and Chiovato L: 
Interferon-γ and tumor necrosis factor-α sustain secretion of 
specific CXC chemokines in human thyrocytes: A first step 
toward a differentiation between autoimmune and tumor-related 
inflammation? J Clin Endocrinol Metab 98: 308‑313, 2013. 
13. Antao-Menezes A, Turpin EA, Bost PC, Ryman-Rasmussen JP 
and Bonner JC: STAT‑1 signaling in human lung fibroblasts is 
induced by vanadium pentoxide through an IFN-beta autocrine 
loop. J Immunol 180: 4200-4207, 2008. 
14. Ingram JL, Antao-Menezes A, Turpin EA, Wallace DG, 
Mangum JB, Pluta LJ, Thomas RS and Bonner JC: Genomic 
analysis of human lung fibroblasts exposed to vanadium pent-
oxide to identify candidate genes for occupational bronchitis. 
Respir Res 8: 34, 2007. 
15. Garcià-Lòpez MA, Sancho D, Sànchez-Madrid F and 
Marazuela M: Thyrocytes from autoimmune thyroid disorders 
produce the chemokines IP-10 and Mig and attract CXCR3+ 
lymphocytes. J Clin Endocrinol Metab 86: 5008-5016, 2001. 
16. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, 
Sebastiani M, Franzoni F, Galetta F and Ferrannini E: High 
values of CXCL10 serum levels in patients with hepatitis C 
associated mixed cryoglobulinemia in presence or absence of 
autoimmune thyroiditis. Cytokine 42: 137-143, 2008. 
17. Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Santini E, 
Franceschini SS and Ferrannini E: Monokine induced by inter-
feron gamma (IFNgamma) (CXCL9) and IFNgamma inducible 
T-cell alpha-chemoattractant (CXCL11) involvement in Graves' 
disease and ophthalmopathy: Modulation by peroxisome prolif-
erator-activated receptor-gamma agonists. J Clin Endocrinol 
Metab 94: 1803-1809, 2009. 
18. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, 
Buonamano A, Ferrannini E and Serio M: High levels of circu-
lating CXC chemokine ligand 10 are associated with chronic 
autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol 
Metab 89: 5496-5499, 2004. 
19. Antonelli A, Ferrari SM, Frascerra S, Pupilli C, Mancusi C, 
Metelli MR, Orlando C, Ferrannini E and Fallahi P: CXCL9 
and CXCL11 chemokines modulation by peroxisome prolifer-
ator-activated receptor-alpha agonists secretion in Graves' and 
normal thyrocytes. J Clin Endocrinol Metab 95: E413-E420, 
2010. 
20. Quent VM, Loessner D, Friis T, Reichert JC and Hutmacher DW: 
Discrepancies between metabolic activity and DNA content as 
tool to assess cell proliferation in cancer research. J Cell Mol 
Med 14: 1003-1013, 2010. 
21. Kemp EH, Metcalfe RA, Smith KA, Woodroofe MN, Watson PF 
and Weetman AP: Detection and localization of chemokine 
gene expression in autoimmune thyroid disease. Clin Endocrinol 
(Oxf) 59: 207-213, 2003. 
22. Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, 
Fioravanti A, Sartini S, Minuto M, Piaggi S, Corti A, et al: 
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibi-
tors with antitumoral activity in vitro and in vivo in papillary 
dedifferentiated thyroid cancer. J Clin Endocrinol Metab 96: 
E288-E296, 2011. 
23. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, 
Barani L, Marchetti I, Ferrannini E and Miccoli P: Primary cell 
cultures from anaplastic thyroid cancer obtained by fine‑needle 
aspiration used for chemosensitivity tests. Clin Endocrinol 
(Oxf) 69: 148-152, 2008. 
24. Antonelli A, Ferrari SM, Corrado A, Ferrannini E and Fallahi P: 
CXCR3, CXCL10 and type 1 diabetes. Cytokine Growth Factor 
Rev 25: 57-65, 2014. 
25. Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C and 
Fallahi P: Chemokine (C-X-C motif) ligand (CXCL)10 in auto-
immune diseases. Autoimmun Rev 13: 272-280, 2014. 
26. Fallahi P, Ferrari SM, Ruffilli I, Elia G, Biricotti M, Vita R, 
Benvenga S and Antonelli A: The association of other autoim-
mune diseases in patients with autoimmune thyroiditis: Review of 
the literature and report of a large series of patients. Autoimmun 
Rev 15: 1125-1128, 2016. 
27. Antonelli A, Fallahi P, Delle Sedie A, Ferrari SM, Maccheroni M, 
Bombardieri S, Riente L and Ferrannini E: High values of Th1 
(CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic 
arthtritis. Clin Exp Rheumatol 27: 22-27, 2009. 
28. Jayaprakash K, Demirel I, Gunaltay S, Khalaf H and Bengtsson T: 
PKC, ERK/p38 MAP kinases and NF-κB targeted signalling 
play a role in the expression and release of IL-1β and CXCL8 
in Porphyromonas gingivalis-infected THP1 cells. APMIS 125: 
623-633, 2017. 
29. Shen T, Yang Z, Cheng X, Xiao Y, Yu K, Cai X, Xia C and Li Y: 
CXCL8 induces epithelial-mesenchymal transition in colon 
cancer cells via the PI3K/Akt/NF-κB signaling pathway. Oncol 
Rep 37: 2095-2100, 2017. 
30. Crescioli C, Sottili M, Bonini P, Cosmi L, Chiarugi P, 
Romagnani P, Vannelli GB, Colletti M, Isidori AM, Serio M, et al: 
Inflammatory response in human skeletal muscle cells: CXCL10 
as a potential therapeutic target. Eur J Cell Biol 91: 139-149, 2012. 
31. Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Piaggi S, 
Gelmini S, Lupi C, Minuto M, Berti P, Benvenga S, et al: 
Dysregulation of secretion of CXC alpha-chemokine CXCL10 
in papillary thyroid cancer: Modulation by peroxisome prolifer-
ator-activated receptor-gamma agonists. Endocr Relat Cancer 16: 
1299-1311, 2009. 
32. Sabbioni E, Kuèera J, Pietra R and Vesterberg O: A critical 
review on normal concentrations of vanadium in human blood, 
serum, and urine. Sci Total Environ 188: 49-58, 1996. 
33. Assem FL and Levy LS: A review of current toxicological 
concerns on vanadium pentoxide and other vanadium compounds: 
Gaps in knowledge and directions for future research. J Toxicol 
Environ Health B Crit Rev 12: 289-306, 2009. 
